Veru is a biopharmaceutical company. Co.'s infectious disease clinical development program includes: COVID-19 patients at risk for acute respiratory distress syndrome; and Sabizabulin, a microtubule disruptor. Co.'s oncology clinical development program includes: breast cancer, which consist of Enobosarm, a selective androgen receptor and Sabizabulin, a microtubule disruptor; and prostate cancer, which include Sabizabulin, a microtubule disruptor, VERU-100, a GnRH antagonist depot and Zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist. Co.'s sexual health program include ENTADFI™, for the treatment of benign prostatic hyperplasia. We show 56 historical shares outstanding datapoints in our coverage of VERU's shares outstanding history.
Understanding the changing numbers of VERU shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VERU versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VERU by allowing them to research VERU shares outstanding history
as well as any other stock in our coverage universe. |
Free VERU Email Alerts:
Video: Shares Outstanding Importance
